

Christopher J A Duncan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9183190/publications.pdf>

Version: 2024-02-01

84
papers

11,618
citations

70961

41
h-index

60497

81
g-index

92
all docs

92
docs citations

92
times ranked

20163
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	6.3	3,887
2	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	6.3	979
3	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	15.2	900
4	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362.	6.3	540
5	Single-cell multi-omics analysis of the immune response in COVID-19. <i>Nature Medicine</i> , 2021, 27, 904-916.	15.2	452
6	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. <i>Cell</i> , 2021, 184, 5699-5714.e11.	13.5	262
7	First experience of COVID-19 screening of health-care workers in England. <i>Lancet, The</i> , 2020, 395, e77-e78.	6.3	261
8	Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. <i>Nature Communications</i> , 2013, 4, 2836.	5.8	256
9	Preliminary Assessment of the Efficacy of a T-Cell-Based Influenza Vaccine, MVA-NP+M1, in Humans. <i>Clinical Infectious Diseases</i> , 2012, 55, 19-25.	2.9	224
10	COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. <i>Lancet Rheumatology, The</i> , 2020, 2, e594-e602.	2.2	200
11	ChAd63-MVA- vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans. <i>Molecular Therapy</i> , 2012, 20, 2355-2368.	3.7	196
12	Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector. <i>Journal of Infectious Diseases</i> , 2012, 205, 772-781.	1.9	194
13	Human IFNAR2 deficiency: Lessons for antiviral immunity. <i>Science Translational Medicine</i> , 2015, 7, 307ra154.	5.8	190
14	Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors. <i>PLoS ONE</i> , 2012, 7, e31208.	1.1	157
15	Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors. <i>Molecular Therapy</i> , 2011, 19, 2269-2276.	3.7	156
16	Macrophage Infection via Selective Capture of HIV-1-Infected CD4+ T Cells. <i>Cell Host and Microbe</i> , 2014, 16, 711-721.	5.1	143
17	Novel coronavirus disease (Covid-19): The first two patients in the UK with person to person transmission. <i>Journal of Infection</i> , 2020, 80, 578-606.	1.7	143
18	T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naïve UK health-care workers: a multicentre prospective cohort study. <i>Lancet Microbe, The</i> , 2022, 3, e21-e31.	3.4	131

#	ARTICLE	IF	CITATIONS
19	The Emerging Threat of Untreatable Gonococcal Infection. <i>New England Journal of Medicine</i> , 2012, 366, 2136-2136.	13.9	100
20	Reduced eosinophil apoptosis in induced sputum correlates with asthma severity. <i>European Respiratory Journal</i> , 2003, 22, 484-490.	3.1	99
21	High-Multiplicity HIV-1 Infection and Neutralizing Antibody Evasion Mediated by the Macrophage-T Cell Virological Synapse. <i>Journal of Virology</i> , 2014, 88, 2025-2034.	1.5	98
22	Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection. <i>Journal of Infection</i> , 2021, 82, e29-e30.	1.7	97
23	Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909. <i>PLoS ONE</i> , 2011, 6, e22271.	1.1	84
24	Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in <i>STAT2</i> . <i>Science Immunology</i> , 2019, 4, .	5.6	80
25	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T _H 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	5.8	80
26	Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 706-714.	1.4	73
27	Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies. <i>Vaccine</i> , 2013, 31, 5789-5797.	1.7	71
28	Comparison of Clinical and Parasitological Data from Controlled Human Malaria Infection Trials. <i>PLoS ONE</i> , 2012, 7, e38434.	1.1	66
29	High multiplicity HIV-1 cell-to-cell transmission from macrophages to CD4+ T cells limits antiretroviral efficacy. <i>Aids</i> , 2013, 27, 2201-2206.	1.0	65
30	Early-onset autoimmune disease due to a heterozygous loss-of-function mutation in <i>TNFAIP3</i> (A20). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 783-786.	0.5	65
31	Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure. <i>PLoS ONE</i> , 2014, 9, e107903.	1.1	65
32	Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 7092.	5.8	65
33	Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with <i>Plasmodium falciparum</i> Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults. <i>PLoS ONE</i> , 2013, 8, e57726.	1.1	64
34	Genetic Lesions of Type I Interferon Signalling in Human Antiviral Immunity. <i>Trends in Genetics</i> , 2021, 37, 46-58.	2.9	58
35	Viral Determinants of HIV-1 Macrophage Tropism. <i>Viruses</i> , 2011, 3, 2255-2279.	1.5	53
36	Comparison of Modeling Methods to Determine Liver-to-blood Inocula and Parasite Multiplication Rates During Controlled Human Malaria Infection. <i>Journal of Infectious Diseases</i> , 2013, 208, 340-345.	1.9	53

#	ARTICLE	IF	CITATIONS
37	Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants. <i>Molecular Therapy</i> , 2016, 24, 1470-1477.	3.7	52
38	Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-endemic Populations. <i>Molecular Therapy</i> , 2014, 22, 1992-2003.	3.7	49
39	Risk factors for failure of outpatient parenteral antibiotic therapy (OPAT) in infective endocarditis. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1650-1654.	1.3	48
40	Controlled Human Blood Stage Malaria Infection: Current Status and Potential Applications. <i>American Journal of Tropical Medicine and Hygiene</i> , 2012, 86, 561-565.	0.6	45
41	National Early Warning Score 2 (NEWS2) to identify inpatient COVID-19 deterioration: a retrospective analysis. <i>Clinical Medicine</i> , 2021, 21, 84-89.	0.8	44
42	Outpatient parenteral antimicrobial therapy with ceftriaxone, a review. <i>International Journal of Clinical Pharmacy</i> , 2012, 34, 410-417.	1.0	43
43	Immune Focusing and Enhanced Neutralization Induced by HIV-1 gp140 Chemical Cross-Linking. <i>Journal of Virology</i> , 2013, 87, 10163-10172.	1.5	43
44	Analysis of human B cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection. <i>Immunology</i> , 2014, 141, 628-644.	2.0	43
45	Acute kidney injury (AKI) associated with intravenous aciclovir in adults: Incidence and risk factors in clinical practice. <i>International Journal of Infectious Diseases</i> , 2018, 74, 97-99.	1.5	42
46	Varicella zoster virus immunity: A primer. <i>Journal of Infection</i> , 2015, 71, S47-S53.	1.7	38
47	Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants. <i>Molecular Therapy</i> , 2017, 25, 547-559.	3.7	34
48	Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	33
49	Prior COVID-19 protects against reinfection, even in the absence of detectable antibodies. <i>Journal of Infection</i> , 2021, 83, 237-279.	1.7	29
50	Microglia Are Essential to Protective Antiviral Immunity: Lessons From Mouse Models of Viral Encephalitis. <i>Frontiers in Immunology</i> , 2019, 10, 2656.	2.2	24
51	A Novel Case of Homozygous Interferon Alpha/Beta Receptor Alpha Chain (IFNAR1) Deficiency With Hemophagocytic Lymphohistiocytosis. <i>Clinical Infectious Diseases</i> , 2022, 74, 136-139.	2.9	24
52	Assessment of Immune Interference, Antagonism, and Diversion following Human Immunization with Biallelic Blood-Stage Malaria Viral-Vectored Vaccines and Controlled Malaria Infection. <i>Journal of Immunology</i> , 2013, 190, 1135-1147.	0.4	23
53	Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2021, 20, 85.	1.7	23
54	Human Disease Phenotypes Associated with Loss and Gain of Function Mutations in STAT2: Viral Susceptibility and Type I Interferonopathy. <i>Journal of Clinical Immunology</i> , 2021, 41, 1446-1456.	2.0	22

#	ARTICLE	IF	CITATIONS
55	Estimated pulse wave velocity improves risk stratification for all-cause mortality in patients with COVID-19. <i>Scientific Reports</i> , 2021, 11, 20239.	1.6	22
56	Control of Eosinophil Toxicity in the Lung. <i>Inflammation and Allergy: Drug Targets</i> , 2005, 4, 481-486.	3.1	21
57	Life-Threatening Influenza, Hemophagocytic Lymphohistiocytosis and Probable Vaccine-Strain Varicella in a Novel Case of Homozygous STAT2 Deficiency. <i>Frontiers in Immunology</i> , 2020, 11, 624415.	2.2	21
58	COVID-19 Management in a UK NHS Foundation Trust with a High Consequence Infectious Diseases Centre: A Retrospective Analysis. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 6.	1.3	21
59	T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	20
60	Antibody and T cell responses associated with experimental human malaria infection or vaccination show limited relationships. <i>Immunology</i> , 2015, 145, 71-81.	2.0	19
61	Aberrant inflammatory responses to type I interferon in STAT2 or IRF9 deficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 955-964.e16.	1.5	19
62	Importance of antimicrobial stewardship to the English National Health Service. <i>Infection and Drug Resistance</i> , 2014, 7, 145.	1.1	13
63	SARS-CoV-2 Testing of 11,884 Healthcare Workers at an Acute NHS Hospital Trust in England: A Retrospective Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 636160.	1.2	13
64	Infectious disease telephone consultations: Numerous, varied and an important educational resource. <i>Journal of Infection</i> , 2007, 54, 515-516.	1.7	12
65	What is the efficacy of the RTS,S malaria vaccine?. <i>BMJ: British Medical Journal</i> , 2011, 343, d7728-d7728.	2.4	12
66	Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults. <i>Journal of Infection</i> , 2022, 85, 306-317.	1.7	12
67	Eosinophils from patients with asthma express higher levels of the pan-leucocyte receptor CD45 and the isoform CD45RO. <i>Clinical and Experimental Allergy</i> , 2003, 33, 936-941.	1.4	11
68	Ceftriaxone-related agranulocytosis during outpatient parenteral antibiotic therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2483-2484.	1.3	11
69	Distinguishing malaria and influenza: Early clinical features in controlled human experimental infection studies. <i>Travel Medicine and Infectious Disease</i> , 2012, 10, 192-196.	1.5	10
70	Tick bite and early Lyme borreliosis. <i>BMJ, The</i> , 2012, 344, e3124-e3124.	3.0	9
71	Pyogenic Spondylodiscitis: Risk Factors for Adverse Clinical Outcome in Routine Clinical Practice. <i>Medical Sciences (Basel, Switzerland)</i> , 2018, 6, 96.	1.3	9
72	Monogenic susceptibility to live viral vaccines. <i>Current Opinion in Immunology</i> , 2021, 72, 167-175.	2.4	8

#	ARTICLE	IF	CITATIONS
73	A decade of vaccinating allergic travellers: A clinical audit. <i>Travel Medicine and Infectious Disease</i> , 2011, 9, 231-237.	1.5	5
74	Futility of CD4+ monitoring in HIV-1 patients with CD4+ cell count above 350 cells/ μ l on suppressive antiretroviral therapy. <i>Aids</i> , 2014, 28, 2638-2639.	1.0	4
75	Host genetic factors in susceptibility to mycobacterial disease. <i>Clinical Medicine</i> , 2014, 14, s17-s21.	0.8	4
76	SARS-CoV-2-Specific T Cell Responses Are Not Associated with Protection against Reinfection in Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, , ASN.2021121587.	3.0	4
77	Incidental Diagnosis in Healthy Clinical Trial Subjects. <i>Clinical and Translational Science</i> , 2012, 5, 348-350.	1.5	2
78	OPAT outcomes in endocarditis. <i>BMJ, The</i> , 2013, 346, f2484-f2484.	3.0	2
79	Vaccination of people with suspected egg allergy is safe and feasible. <i>BMJ: British Medical Journal</i> , 2011, 343, d5780-d5780.	2.4	1
80	Improving targeted screening for hepatitis C in the UK. <i>BMJ, The</i> , 2012, 345, e6525-e6525.	3.0	1
81	The unholy trinity of human herpesvirus 8-associated malignancy in a person living with HIV-1. <i>Aids</i> , 2018, 32, 404-406.	1.0	1
82	Management of infective endocarditis in the OPAT setting; a descriptive analysis. <i>Journal of Infection</i> , 2011, 63, e73-e74.	1.7	0
83	Clinical Evaluation Of New Viral Vectored Vaccines Targeting The Plasmodium Falciparum Blood-Stage Antigens; Msp1 And Ama1. <i>Journal of Infection</i> , 2011, 63, 492-493.	1.7	0
84	Effect of intermittent preventative therapy for secondary prevention of severe malarial anaemia. <i>Lancet Infectious Diseases, The</i> , 2012, 12, 906.	4.6	0